MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-25-2026
AC Immune SA Operating Cash Flow 2011-2026 | ACIU
Annual Operating Cash Flow AC Immune SA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -65.7 M | -59.5 M | 55.2 M | -44.1 M | -22.1 M | -5.65 M | 44.1 M | - | - | - | - |
All numbers in CHF currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55.2 M | -65.7 M | -14 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Aptorum Group Limited
APM
|
-1.84 M | $ 0.88 | - | $ 6.47 M |  China |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.12 | 0.37 % | $ 441 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-831 M | $ 9.7 | 1.09 % | $ 627 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
158 M | $ 21.83 | -2.76 % | $ 3.62 B | USA |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
Burford Capital Limited
BUR
|
181 M | $ 5.0 | 1.42 % | $ 801 M | Britain |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-72.5 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | USA |
 |
Cerus Corporation
CERS
|
4.84 M | $ 2.91 | 43.35 % | $ 555 M | USA |
 |
Caladrius Biosciences
CLBS
|
-19.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
BioNTech SE
BNTX
|
890 M | $ 96.45 | -6.77 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-147 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-58.5 M | $ 1.44 | - | $ 235 M | France |
 |
Dynavax Technologies Corporation
DVAX
|
66.5 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Editas Medicine
EDIT
|
-165 M | $ 2.9 | -3.33 % | $ 257 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.04 | -4.7 % | $ 5 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
-74.5 M | - | -9.21 % | $ 2.55 M | USA |
 |
Edesa Biotech
EDSA
|
-4.89 M | $ 18.7 | 2.33 % | $ 59.8 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-31.8 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Evogene Ltd.
EVGN
|
-24.7 M | $ 0.78 | -0.37 % | $ 27.9 M | Israel |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |